FCM
PRME icon

Farallon Capital Management’s Prime Medicine PRME Stock Holding History

Farallon Capital Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.58M Hold
1,240,843
– – 0.02% 70
2026
Q1 		$4.32M Hold
1,240,843
– – 0.02% 95
2025
Q4 		$4.31M Sell
1,240,843
-3,509,157
-74% -$15.6M 0.02% 78
2025
Q3 		$26.3M Buy
4,750,000
+4,000,000
+533% +$16.3M 0.11% 70
2025
Q2 		$1.85M Hold
750,000
– – 0.01% 86
2025
Q1 		$1.49M Hold
750,000
– – 0.01% 88
2024
Q4 		$2.19M Hold
750,000
– – 0.01% 95
2024
Q3 		$2.9M Hold
750,000
– – 0.01% 99
2024
Q2 		$3.85M Hold
750,000
– – 0.02% 95
2024
Q1 		$5.25M Buy
+750,000
New +$5.69M 0.02% 101

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Farallon Capital Management's PRME Position: Q2 2026 in Review

Farallon Capital Management held its Prime Medicine (PRME) position steady in Q2 2026 at 1,240,843 shares worth $4.58M. The position accounts for 0.02% of the portfolio, ranked #70.

Farallon Capital Management first reported a position in PRME in Q1 2024 and has held it in 10 quarters since. The position peaked at $26.3M in Q3 2025. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Farallon Capital Management held 1,240,843 shares of Prime Medicine worth $4.58M as of Q2 2026.
  • Farallon Capital Management left its Prime Medicine share count unchanged in Q2 2026.
  • Prime Medicine made up 0.02% of Farallon Capital Management's portfolio in Q2 2026, its #70 holding.
  • Farallon Capital Management first reported a position in Prime Medicine in Q1 2024 and has held it in 10 quarters since.
  • Farallon Capital Management's Prime Medicine position peaked at $26.3M in Q3 2025.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.